
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
AI Summary
- About


BioLineRx Ltd (BLRX)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
02/14/2025: BLRX (1-star) is currently NOT-A-BUY. Pass it for now.
Analysis of Past Performance
Type Stock | Historic Profit 18.76% | Avg. Invested days 25 | Today’s Advisory PASS |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 13.20M USD | Price to earnings Ratio - | 1Y Target Price 182.67 |
Price to earnings Ratio - | 1Y Target Price 182.67 | ||
Volume (30-day avg) 410293 | Beta 0.99 | 52 Weeks Range 3.24 - 57.60 | Updated Date 02/15/2025 |
52 Weeks Range 3.24 - 57.60 | Updated Date 02/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -12.68 |
Earnings Date
Report Date 2025-02-04 | When Before Market | Estimate - | Actual - |
Profitability
Profit Margin -90.57% | Operating Margin (TTM) -108.98% |
Management Effectiveness
Return on Assets (TTM) -32.96% | Return on Equity (TTM) -184.09% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 12943615 | Price to Sales(TTM) 0.6 |
Enterprise Value 12943615 | Price to Sales(TTM) 0.6 | ||
Enterprise Value to Revenue 0.59 | Enterprise Value to EBITDA -0.67 | Shares Outstanding 3558500 | Shares Floating 1142506606 |
Shares Outstanding 3558500 | Shares Floating 1142506606 | ||
Percent Insiders 4.67 | Percent Institutions 2.1 |
AI Summary
BioLineRx Ltd.: A Comprehensive Overview
Company Profile:
Detailed history and background: Founded in 1996, BioLineRx Ltd. (BLRX) is a clinical-stage biopharmaceutical company focused on discovering and developing immunotherapies and targeted small molecule drugs to address unmet medical needs in oncology and neurology. Headquartered in Petah Tikva, Israel, BLRX has additional offices in the US, Switzerland, and Belgium.
Core business areas: BLRX pursues three core business areas:
- Immuno-oncology: Targeting various cancers with novel immunotherapeutic platforms, such as BL-8040 and OncoFoam, which aim to stimulate the immune system to attack tumor cells.
- Central nervous system (CNS): Developing targeted small molecule drugs for CNS disorders, such as BL-1040 for ALS and BL-1020 for multiple sclerosis.
- Targeted therapeutics: Researching and developing innovative targeted small molecules for oncology and CNS indications, like BL-2520 for non-small cell lung cancer.
Leadership team and corporate structure: The leadership team comprises experienced professionals in the biopharmaceutical industry:
- Morris Beracha, CEO: Extensive experience in leading biopharmaceutical companies.
- Dr. Kinneret Savitsky, CFO: Expertise in finance and accounting within the life sciences industry.
- Dr. Michael Beracha, Chief Medical Officer: Renowned neurologist and researcher.
- Michael E. Tarazi, Chief Operating Officer: Proven leadership in commercial operations and business development.
BioLineRx operates with a board of directors and executive management team, overseeing strategic direction and management.
Top Products and Market Share:
Top products:
- BL-8040: Phase I/IIa clinical stage, a first-in-class immuno-oncology DNA vaccine platform targeting human papillomavirus (HPV) 16-associated cancers.
- OncoFoam: Phase II clinical stage, a sustained-release intratumoral immunotherapy platform designed to enhance the efficacy of chemotherapy and potentially other anti-cancer agents.
- BL-1040: Phase II clinical stage, a small molecule drug candidate for the treatment of Amyotrophic Lateral Sclerosis (ALS).
Market share: BioLineRx's products are primarily in the clinical development phase, with none currently approved for market sale. Therefore, they do not yet hold a market share in the global or US markets.
Product performance and market reception: BL-8040 has demonstrated promising results in early clinical studies, showing a favorable safety profile and potential to induce immune responses against HPV16-associated cancers. OncoFoam data also suggests its potential to enhance the efficacy of chemotherapy and improve patient outcomes. BL-1040 is currently undergoing clinical trials, with initial data showing positive signs for ALS treatment.
Total Addressable Market (TAM):
Market size:
- Global immuno-oncology market: Estimated to reach $159 billion by 2027.
- Global ALS treatment market: Expected to reach $1.3 billion by 2028.
- Global multiple sclerosis treatment market: Projected to reach $35 billion by 2027.
Financial Performance:
Financial statements: BLRX's recent financial statements reflect the company's stage of development, with limited revenue and operating income.
- Revenue: Primarily focused on research and development (R&D) grants and collaborations, with minimal product sales.
- Net income: Negative due to R&D investments and operating expenses.
- Profit margins: Not applicable at this stage.
- Earnings per share (EPS): Negative due to operating losses.
Year-over-year comparison: Financial performance has shown growth in R&D spending and overall expenses due to clinical trial advancements.
Cash flow and balance sheet:
- Cash flow: Primarily funded through public stock offerings and collaborations.
- Balance sheet: Shows limited cash reserves with a dependence on external financing.
Dividends and Shareholder Returns:
Dividends: Currently, BioLineRx does not distribute dividends due to its development stage.
Shareholder returns: BLRX's stock has experienced volatility due to its early-stage development and dependence on clinical trial results.
Growth Trajectory:
Historical growth: Primarily driven by R&D progress and clinical trial advancements.
Future projections: Dependent on the success of ongoing clinical trials and potential market approvals. New products and strategic partnerships will influence future growth.
Market Dynamics:
Industry trends:
- Increasing demand for personalized medicine and targeted therapies.
- Growing focus on immunotherapy and novel treatment approaches.
- Technological advancements in drug discovery and development.
Company positioning: BLRX is positioned within the immuno-oncology and CNS therapeutics segments, targeting significant unmet needs. Its focus on innovative technologies and strategic partnerships could position it for future success.
Competitors:
Key competitors:
- Immuno-oncology:
- Checkmate Pharmaceuticals (CKMT)
- Novavax (NVAX)
- Adaptimmune Therapeutics (ADAP)
- CNSerapeutics:
- Amylyx Pharmaceuticals (AMLX)
- Biogen (BIIB)
- Novartis (NVS)
Market share comparison: As BLRX's products are not yet on the market, a direct market share comparison is not applicable.
Competitive advantages and disadvantages:
Advantages:
- Proprietary technology platforms for immunotherapy and targeted small molecules.
- Experienced management team and strategic partnerships.
- Potential for high-impact therapies in attractive market segments.
Disadvantages:
- Early-stage development with clinical trials underway.
- Limited product revenue and profitability.
- Dependence on external financing.
Potential Challenges and Opportunities:
Challenges:
- Demonstrating clinical efficacy and safety of its product candidates.
- Securing regulatory approvals for market access.
- Maintaining financial resources for R&D and commercialization.
Opportunities:
- Potential for market approvals of its product candidates.
- Expanding product portfolio through internal R&D and collaborations.
- Building a strong commercial infrastructure to prepare for market entry.
Recent Acquisitions:
No acquisitions reported for BioLineRx Ltd. within the last three years.
AI-Based Fundamental Rating:
Rating: 6/10
Justification: BioLineRx holds promise with its innovative technologies and target markets. However, its early-stage development, lack of product revenue, and dependence on external funding introduce risks. The successful completion of clinical trials, product approvals, and market entry will be crucial factors influencing its future success.
Sources:
- BioLineRx Ltd. website: https://www.biolinerx.com/
- SEC filings: https://www.sec.gov/edgar/search/#/company?text=BioLineRx+Ltd%2C
- Market research reports: https://www.grandviewresearch.com/
- Zacks Investment Research: https://www.zacks.com/stock/research/BLRX
Disclaimer: This analysis is for informational purposes only and should not be considered investment advice. Investing in early-stage biopharmaceutical companies involves significant risk. Please consult a qualified financial professional for individualized advice.
About BioLineRx Ltd
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2011-07-25 | CEO - | ||
Sector Healthcare | Industry Biotechnology | Full time employees 79 | Website https://www.biolinerx.com |
Full time employees 79 | Website https://www.biolinerx.com |
BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It also develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.